iShares Biotechnology ETF

First Trust NYSE Arca Biotechnology Index Fund offers a more concentrated portfolio with only 30 holdings compared to the 248 positions in iShares Biotechnology ETF iShares Biotechnology ETF is the larger and more established fund, having launched in 2001 and managing $9.6 billion in assets under management First Trust NYSE Arca Biotechnology Index Fund has achieved a higher total return over both one-year and five-year horizons

fool.com - 2026-07-12 15:30:01

The iShares U.S. Pharmaceuticals ETF (IHE) offers a lower expense ratio and a significantly higher dividend yield than the iShares Biotechnology ETF (IBB). IBB offers broader diversification, with 248 holdings compared to just 56 for IHE.

fool.com - 2026-07-10 06:41:28

Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.

barrons.com - 2026-07-06 14:04:00

Janus Henderson portfolio manager Dan Lyons discusses why he sees opportunities for market outperformance in the healthcare sector as innovations in biotechnology, pharmaceuticals and medical devices proliferate. Check out our daily newsletter!

youtube.com - 2026-07-02 15:55:36

State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.44% for iShares Biotechnology ETF. iShares' ETF provides concentrated exposure to 248 biotechnology stocks while the SPDR fund holds 59 diverse healthcare names.

fool.com - 2026-07-02 07:45:01

Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.

seekingalpha.com - 2026-06-29 17:00:00

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.

zacks.com - 2026-06-29 12:11:05

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.

zacks.com - 2026-06-29 07:20:22

The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.

zacks.com - 2026-06-23 17:21:05

The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging.

etftrends.com - 2026-06-23 16:34:36

U.S. stocks splintered Tuesday as a violent global sell-off in semiconductor shares hammered the Nasdaq, even as a rotation into defensive sectors and small caps kept the Dow Jones in positive territory through midday trading.

benzinga.com - 2026-06-23 12:45:55

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on February 5, 2001.

zacks.com - 2026-06-22 07:20:43

Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC.  Many biotech companies are now pursuing a dual-track process: preparing for an IPO while simultaneously engaging with potential acquirers.

cnbc.com - 2026-06-16 01:00:01

I reiterate a Hold rating on the iShares Nasdaq Biotechnology ETF, citing modest valuation but lackluster momentum and unfavorable market themes. IBB lags the S&P 500 YTD and faces headwinds as speculative capital favors AI and space stocks over biotech. The ETF's technical setup is mixed, with key resistance at $170 and potential upside to $190 if a breakout occurs.

seekingalpha.com - 2026-06-15 15:52:56

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

etftrends.com - 2026-06-11 07:14:42

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

zacks.com - 2026-06-10 13:01:19

LONDON--(BUSINESS WIRE)---- $IBB #AVLSOM3--AV Laboratories, a science-led skincare company founded by pioneers in IVF solutions, regenerative medicine, and stem cell therapy, today announced it will exhibit at the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE 2026, taking place in London from 5 - 8 July 2026. The company will welcome clinicians, embryologists, fertility specialists, researchers, partners, and industry participants at Booth A22. “ESHRE is deeply personal.

businesswire.com - 2026-05-21 09:27:00

The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.

wsj.com - 2026-05-20 05:30:00

Locking in profits while you have them can help avoid downturns.

investors.com - 2026-05-01 15:08:26

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund launched on June 19, 2006.

zacks.com - 2026-04-30 07:21:08

The iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

zacks.com - 2026-04-28 07:20:36

Biotech has reasserted itself over the past year as drug approvals,

247wallst.com - 2026-04-23 13:22:32

Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.

fool.com - 2026-04-21 15:26:26

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on February 5, 2001.

zacks.com - 2026-04-21 07:20:24